Board of Directors
Bryan Roberts, PhD
Chairman and Co-Founder
Bryan Roberts, Ph.D., joined Venrock as a Kauffman Fellow in 1997. He is based in Venrock’s Palo Alto office and focuses on a broad range of health care investments. Bryan is currently Chairman of the Board of Directors of Achaogen, Castlight Health, and Ironwood Pharmaceuticals (NASDAQ: IRWD) and also serves on the Boards of several other private companies, including CodeRyte, Ikaria, Intarcia, PowerVision, Tandem Diagnostics, and Zeltiq. Past investments include athenahealth (NASDAQ: ATHN), Illumina (NASDAQ: ILMN), Sirna Therapeutics (acquired by Merck) and Xenoport (NASDAQ: XNPT). Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and has been the highest-ranking health care investor on Forbes’ Midas List since 2008.
Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University and received his B.A. from Dartmouth College. He also previously held positions in corporate finance at Kidder, Peabody & Co.
Managing Partner, Oak Investment Partners
Annie Lamont, Managing Partner, joined Oak Investment Partners in 1982 and served as General Partner from 1986 to 2006. Annie leads the health care and financial services technology teams at Oak.
Annie’s recent investments include Acculynk, Argus Information & Advisory Services, Benefitfocus, Castlight Health, iHealth Technologies, NetSpend, PayFlex, PharMEDium Healthcare, Radisphere National Radiology Group, TxVia and Vesta. Prior investments include athenahealth, American Esoterics, CareMedic, CLARiENT, Harbor Payments, Health Dialog, Odyssey Healthcare, Oak Tree/Oxford, Point Carbon, Psychiatric Solutions and United BioSource.
Earlier in Annie’s venture career, she developed a number of successful biopharmaceutical investments (Cephalon, ViroPharma, Esperion).
Prior to joining Oak, Annie was a research associate with Hambrecht & Quist and received her B.A. in Political Science from Stanford University. Annie currently serves on the Stanford University Board of Trustees. She has been ranked among the top 25 in Forbes Midas List of all venture investors and has also served on the Executive Board of the National Venture Capital Association.
David B. Singer
Limited Partner, Maverick Capital
Mr. Singer is responsible for Maverick’s Private Investments globally. He joined Maverick in 2004 from Oscient Pharmaceutical Corporation, where he was Chairman of the Board. Mr. Singer is a founder and former CEO of three healthcare companies: Affymetrix, Inc., Corcept Therapeutics, Inc., and Genesoft Pharmaceuticals, Oscient’s predecessor. Mr. Singer currently serves on the boards of several private companies.
Mr. Singer received a B.A. from Yale University and an M.B.A. from Stanford University. He was a Crown Fellow of the Aspen Institute, and is currently a Sterling Fellow of Yale University and a director of College Track.
Christopher P. Michel
Managing Director, Nautilus Ventures
Chris Michel is the Managing Director of Nautilus Ventures, a technology focused venture fund. Previously, Chris founded two companies: Military.com, the nation’s largest community for military personnel; and Affinity Labs, a portfolio of web communities serving professional groups. Monster Worldwide acquired both companies. Chris serves on the boards of IDG, Kixeye, Dale Carnegie, and the USO. He is also an advisor to the Oxford Internet Institute at Oxford University and the Center for Investigative Reporting. He was previously the Entrepreneur-in-Residence at Harvard Business School.
A former Naval Flight Officer in the United States Navy, Chris earned his commission from the NROTC program at the University of Illinois at Urbana-Champaign and holds an M.B.A. from the Harvard Business School. Chris is also a fellow of the Aspen Institute and a life member of the Council on Foreign Relations.
David Ebersman is responsible for the finance, accounting, investor relations, real estate, and information technology functions at Facebook. Prior to Facebook, David worked at Genentech for nearly 15 years, most recently as CFO and executive vice president. Before joining Genentech’s finance organization in 2006, he was senior vice president of Product Operations. David earned a B.A. in Economics and International Relations from Brown University.
Robert Kocher, MD
Bob Kocher is one of the nation’s leading experts in health care policy and most prominent motivators of reform. Before joining Venrock as partner, Kocher served in the Obama Administration as special assistant to the President for health care and economic policy and a member of the National Economic Council. He helped shape the Affordable Care Act, focusing on cost, quality and delivery system reform, and was a key driver of the Heath Data Initiative, among other health care programs and innovations. Kocher was also a partner at McKinsey and Company, where he led the McKinsey Center for Health Reform. He received his M.D. from George Washington University and completed his residency in internal medicine at Harvard Medical School and Beth Israel Deaconess Medical Center in Boston.
Giovanni Colella, MD
Co-Founder and CEO
Giovanni Colella co-founded Castlight in 2008, along with Todd Park (currently CTO of the U.S. Department of Health and Human Services). Prior to founding Castlight, Giovanni was Founder, President and CEO of RelayHealth, which was acquired by McKesson.
Giovanni is a Diplomate of the American Board of Psychiatry and Neurology. He graduated with an M.D. from the Universita Degli Studi di Milano in Italy, did his fellowship in Public Health at Columbia University, and earned his M.B.A. from Columbia Business School.